1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial
Listen to this summary
The OPTIMA-AF trial aimed to determine whether 1-month dual antithrombotic therapy followed by direct oral anticoagulant (DOAC) monotherapy is as effective and safer than 12-month dual therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI). The results indicated that the 1-month regimen was non-inferior in preventing death or thromboembolic events and significantly reduced the incidence of major or clinically relevant non-major bleeding, suggesting a favorable clinical profile for the shorter treatment duration.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Jul 23, 2026 · Lancet (London, England)
Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial
Jul 22, 2026 · Lancet (London, England)
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial
Jul 17, 2026 · Lancet (London, England)
Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial
Jul 13, 2026 · Lancet (London, England)
Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial
Jul 10, 2026 · Lancet (London, England)
Advancing the relevance of clinical trials for older patients
Jul 9, 2026 · Lancet (London, England)
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial
More in Nuclear Medicine
View all →Jul 22, 2026 · The New England journal of medicine
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Jul 22, 2026 · The New England journal of medicine
Antiretroviral Therapy
Jul 18, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Incremental prognostic value of the hemodynamic gain index in patients undergoing exercise stress myocardial perfusion imaging
Jul 15, 2026 · The New England journal of medicine
Andes Virus - A Clinical Review
Jul 15, 2026 · The New England journal of medicine
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
Jul 15, 2026 · The New England journal of medicine
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
